Title of article :
New drugs and targeted treatments in Hodgkin’s lymphoma
Author/Authors :
Provencio، نويسنده , , Mariano and Sلnchez-Zapata، نويسنده , , Antonio and Sلnchez-Beato، نويسنده , , Margarita، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2014
Abstract :
New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin’s lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and m-TOR inhibitors.
Keywords :
lenalidomide , m-TOR inhibitors , Target treatments , Hodgkin’s lymphoma , Brentuximab vedotin , Deacetylase inhibitors , Bendamustine
Journal title :
Cancer Treatment Reviews
Journal title :
Cancer Treatment Reviews
